 |
BioWorld-Insight-2002-06-03
'Wild' Panel Meeting's Decision Boosts Amevive In Psoriasis Race
'Wild' Panel Meeting's Decision Boosts Amevive In Psoriasis Race
Hardly had the House passed the Prescription Drug User Fee Act - clearing the way for the next day's approval by the Senate - than all eyes turned from PDUFA to Amevive, Biogen Inc.'s fusion protein for psoriasis. (BioWorld Financial Watch)
Biotech Corporate Collaborations In Agriculture: New, Revised Agreements, Dec. 27, 2001 - May 30, 2002
No Abstract